Logo

Sygnis TruePrime WGA Kit

Feb 23, 2015

Sygnis has launched the TruePrime WGA kit for whole-genome amplification of entire genomes from various sample types.

The TruePrime technology is based on multiple displacement amplification (MDA) of DNA or RNA species from a variety of samples. TruePrime combines Sygnis' recently discovered DNA primase TthPrimPol with its Phi29 polymerase, and does not require the use of any synthetic random primers. The new kit eliminates common artifacts linked to the use of oligonucleotides, reduces amplification bias, is insensitive to external DNA contaminations, and has a high reproducibility, the company said. These features make it attractive for researchers who are working with limited sample volumes but do not need to obtain DNA from individual cells, Sygnis added.

The TruePrime WGA kit is available globally through distributors as well as through Sygnis' TruePrime online shop. It is available in 25- or 100-reaction formats.

Sygnis also previously launched a TruePrime kit for amplification of DNA from single cells.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.